Pyridam Farma Tbk PT
IDX:PYFA

Watchlist Manager
Pyridam Farma Tbk PT Logo
Pyridam Farma Tbk PT
IDX:PYFA
Watchlist
Price: 496 IDR 2.9% Market Closed
Market Cap: 5.6T IDR

Pyridam Farma Tbk PT
Note Receivable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Pyridam Farma Tbk PT
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Pyridam Farma Tbk PT
IDX:PYFA
Note Receivable
Rp23.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Tempo Scan Pacific Tbk PT
IDX:TSPC
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kalbe Farma Tbk PT
IDX:KLBF
Note Receivable
Rp300.1B
CAGR 3-Years
84%
CAGR 5-Years
55%
CAGR 10-Years
21%
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
Note Receivable
Rp9.9B
CAGR 3-Years
12%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Soho Global Health Tbk PT
IDX:SOHO
Note Receivable
Rp998m
CAGR 3-Years
-76%
CAGR 5-Years
-69%
CAGR 10-Years
N/A
Kimia Farma Tbk PT
IDX:KAEF
Note Receivable
Rp42.4B
CAGR 3-Years
100%
CAGR 5-Years
35%
CAGR 10-Years
75%
No Stocks Found

Pyridam Farma Tbk PT
Glance View

Market Cap
5.6T IDR
Industry
Pharmaceuticals

PT Pyridam Farma Tbk engages in the production and development of pharmaceutical medicines, and trading of medical supplies. The company is headquartered in Jakarta, Dki Jakarta and currently employs 1,539 full-time employees. The company went IPO on 2001-10-16. The firm operates through two segments: Pharmaceutical Products and Toll Manufacturing Services, and Medical Device Products. Its business consists of production and/or distribution of modern and traditional medicines and distribution of medical devices, such as laboratory equipment and PCR test kits. The company offers products across consumer health, prescription, pyfaesthetic and biomedilab categories. The company produces various kinds of pharmaceuticals products ranging from antibiotics, vitamins and health supplements. The firm offers its products in the form of effervescent tablets, capsules, caplets, syrups and creams. Its prescription production has several properties, such as anti-infection, anti-inflammatory, anti-parkinsonian, anti-epileptic, and other indications. The company provides toll manufacturing services to produce products owned by the Company’s partner companies in accordance with predetermined specifications.

PYFA Intrinsic Value
499.62 IDR
Undervaluation 1%
Intrinsic Value
Price

See Also

What is Pyridam Farma Tbk PT's Note Receivable?
Note Receivable
23.2B IDR

Based on the financial report for Sep 30, 2025, Pyridam Farma Tbk PT's Note Receivable amounts to 23.2B IDR.

Back to Top